Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III.
Connective tissue-activating peptide III (CTAP III), a CXC chemokine derived from the chemokine precursor platelet basic protein (PBP) by proteolytic cleavage, has been identified in platelets, activated macrophages, neutrophils and T lymphocytes. CTAP III can support stem cell-derived haematopoiesis yet inhibits the proliferation of committed megakaryocyte (MK) progenitors. This investigation was aimed at characterizing CTAP III expression in human MKs and determining it's role in MK differentiation. We report high expression of CTAP III in mature human bone marrow (BM) MKs and megakaryoblast cell lines following differentiation induction with phorbol ester 12-myristate 13-acetate (PMA). Immunostaining with anti-CTAP III antibodies demonstrated its prominent presence in platelet producing zones in the cytoplasm and intense staining around the periphery of the large BM MKs. In cultures of logarithmically growing megakaryoblast cell lines DAMI, CHRF-288 or MEG01, which contain primarily 2N cells, only 15% of the cells expressed CTAP III. The addition of PMA stimulated high levels of CTAP III after 24 h in more than 75% of the cells, being expressed in both the 2N and large polyploid MKs. Reverse transcription polymerase chain reaction (RT-PCR) revealed upregulation of CTAP III mRNA after only 1 h of exposure to PMA that was sustained for 24 h. In the bone marrow of idiopathic thrombocytopenic pupura (ITP) patients undergoing accelerated MK maturation and thrombopoiesis, 99% of large MKs and 95% of small MKs expressed high levels of CTAP III. While the biological function of this chemokine in MKs is not known, these studies demonstrate that molecular upregulation of CTAP III in MKs is associated with maturation and, as with other chemokines, may be involved in proliferation arrest and cellular interactions with extracellular matrix and platelet production.
Deutsch
V
V
The Haematology Institute, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel. varda@tamsc.health.gov.il
Bitan
M
M
Friedmann
Y
Y
Eldor
A
A
Vlodavsky
I
I
D001779:Blood Coagulation Factors / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D001792:Blood Platelets / Q000737:chemistry / Q000378:metabolism; D001854:Bone Marrow Cells / Q000502:physiology; D002452:Cell Count; D002454:Cell Differentiation / Q000502:physiology; D002460:Cell Line; D006801:Humans; D007150:Immunohistochemistry; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D008533:Megakaryocytes / Q000502:physiology*; D008954:Models, Biological; D010455:Peptides; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D001779:Blood Coagulation Factors; D010455:Peptides; D012333:RNA, Messenger; C009862:connective tissue-activating peptide; C018329:low affinity platelet factor 4; D013755:Tetradecanoylphorbol Acetate